The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2022 | Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
In this discussion, leading experts Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, Suzanne Trudel, MD, MSc, Princess Margaret Cancer Centre, Toronto, Canada, and Frederick Locke, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, share their highlights from the lymphoma and myeloma sessions that took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL. The experts share their excitement for the practice-changing trial data demonstrating the benefit of CAR-T therapy in second line in large B-cell lymphoma (LBCL), as well as for the possibility of approaching a cure in follicular lymphoma (FL). They then move on to discuss strategies to overcome the challenges associated with CAR-T therapy in multiple myeloma, including allogeneic CAR-Ts, where they discuss emerging data on various allogeneic CAR-T products. The experts then comment on the potential of bispecific antibodies in myeloma and how patients might be selected to receive BCMA-directed CAR-T therapy or bispecific antibodies in the future. Finally, the experts discuss real-world data on CAR-T therapy for mantle cell lymphoma (MCL) and multiple myeloma.
